Noile-Immune Biotech Inc
TSE:4893
Noile-Immune Biotech Inc
Other Items
Noile-Immune Biotech Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Noile-Immune Biotech Inc
TSE:4893
|
Other Items
-¥378k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Other Items
-¥298.2m
|
CAGR 3-Years
-179%
|
CAGR 5-Years
-394%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Other Items
-¥2.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
PeptiDream Inc
TSE:4587
|
Other Items
-¥299.2m
|
CAGR 3-Years
77%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Other Items
-¥6.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Other Items
-¥4.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Noile-Immune Biotech Inc
Glance View
Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
See Also
What is Noile-Immune Biotech Inc's Other Items?
Other Items
-378k
JPY
Based on the financial report for Dec 31, 2025, Noile-Immune Biotech Inc's Other Items amounts to -378k JPY.
